Clinical trials: Heparin
Covid19
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with anticoagulant, anti-inflammatory and potential…
- Trial name
- ASPEN (NCT04655586)
- Testing
- rNAPc2, Heparin
- Where
- 24 sites in United States, Argentina and 1 more
- Volunteers
- 160 people
- Sponsor
- ARCA Biopharma, Inc.
Heparin-Induced Thrombocytopenia
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
The purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).
- Trial name
- NCT00673439
- Testing
- fondaparinux, warfarin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Louisville
Thromboembolism
Self-management of Low Molecular Weight Heparin Therapy
There is very little data available on compliance with self-injected low molecular weight heparins (LMWH), but what there is, definitely shows that compliance represents a significant problem.
- Trial name
- NCT00794560
- Testing
- patient education
- Where
- 2 sites in Switzerland
- Volunteers
- 154 people
- Sponsor
- University Hospital, Basel, Switzerland
Venous Thromboembolic Disease, Deep Vein Thrombosis
Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
The rate of venous thromboembolic events in trauma patients at high risk for deep vein thrombosis and pulmonary embolism receiving low dose unfractionated heparin every 8 hours will be equivalent or less than a similar group of…
- Conditions
- Venous Thromboembolic Disease, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT01729559
- Testing
- 5000 Units unfractionated Heparin Q 8 hr, 30mg enoxaparin Q12 hr
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Scripps Health
Acute ST Elevation Myocardial Infarction
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
The purpose of this study is to compare unfractionated heparin (UFH) and bivalirudin in the performance and subsequent outcomes of Primary percutaneous coronary intervention. This will be a pragmatic trial.
- Trial name
- HEAT-PPCI (NCT01519518)
- Testing
- unfractionated heparin, Bivalirudin
- Where
- United Kingdom
- Volunteers
- 1,829 people
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Coagulation; Intravascular
Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass
The purpose of this study is to compare two different dosing strategies of a drug named protamine.
- Trial name
- NCT05426031
- Testing
- Protamine fixed dose, Protamine ratio dose
- Where
- 2 sites in United States
- Volunteers
- 130 people
- Sponsor
- University of Miami
Thromboembolic Events
Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device
To demonstrate the substantial equivalence (SE) of Pefakit® PiCT® UC (test device, T) to aPTT-SP (Hemosil) (predicate device, P) in determining heparin levels in subjects undergoing heparin therapy in support of a United States…
- Trial name
- NCT02052544
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 123 people
- Sponsor
- dsm-firmenich Switzerland AG
Covid19
Nebulized Heparin for COVID19-associated Acute Respiratory Failure
The objective of the current study is to investigate the utilization of nebulized heparin to circumvent pathologic changes in COVID-19 and prevent harmful effects possible with systemic anticoagulation.
- Trial name
- NCT04842292
- Testing
- Heparin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brittany Bissell
Thromboembolism
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery.
- Trial name
- NCT06118957
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Utah
Acute Coronary Syndrome
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST…
- Trial name
- FUTURA/OASIS 8 (NCT00790907)
- Testing
- fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 3,235 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndromes
Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI
The primary objective of this clinical trial is to evaluate safety of switching from fondaparinux to either unfractionated heparin or bivalirudin for patients experiencing acute coronary syndrome undergoing percutaneous coronary…
- Trial name
- SWITCHIII (NCT00464087)
- Testing
- Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
- Where
- 7 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Medstar Health Research Institute
Antiphospholipid Syndrome in Pregnancy, Pregnancy Loss
AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study
The APPLE pilot trial is a feasibility study that is a multicentre, open-label, randomized controlled trial. Pregnant women with antiphospholipid syndrome (APS) and a history of late (≥10 weeks gestation) or recurrent early (2…
- Trial name
- APPLE (NCT03100123)
- Testing
- Aspirin 81 mg, Low-molecular-weight heparin
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Ottawa Hospital Research Institute
Arthritis, Osteoarthritis, Knee
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in…
- Conditions
- Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
- Trial name
- NCT01094886
- Testing
- Rivaroxaban
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Coronary Artery Disease (CAD)
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
The primary objective is to evaluate the safety and feasibility of using M118 as an anticoagulant in the target population of subjects with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI).
- Trial name
- EMINENCE (NCT00543400)
- Testing
- M118, Unfractionated Heparin
- Where
- 44 sites in United States, Canada
- Volunteers
- 503 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Covid19
Enriched Heparin Anti COVID-19 Trial
Coronavirus 19 (COVID-19) is a viral respiratory disease that was identified in December 2019 after the first cases in China, spreading rapidly until reaching pandemic status, causing the collapse of numerous health systems and…
- Trial name
- EnHanCed (NCT04743011)
- Testing
- Heparin sodium
- Where
- 2 sites in Brazil
- Volunteers
- 27 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Heparin Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
HIT-RADIO is a study of patients who had a positive heparin PF-4 antibody test between 1/21/2008 and 9/25/2008 at selected hospitals.
- Trial name
- HIT-RADIO (NCT01178333)
- Where
- 21 sites in United States
- Volunteers
- 668 people
- Sponsor
- Carelon Research
Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II
The purpose of this retrospective registry is to collect data about patients with acute HIT II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid, Argatroban or Fondaparinux.
- Trial name
- NCT01304238
- Testing
- lepirudin, danaparoid, argatroban
- Volunteers
- 195 people
- Sponsor
- GlaxoSmithKline
Thrombocytopenia
Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)
Heparin-induced thrombocytopenia (HIT), a condition characterized by low platelet levels and possible blood clots, occurs in a small number of people after treatment with the drug heparin.
- Trial name
- HOT (NCT00594685)
- Where
- 21 sites in United States
- Volunteers
- 10 people
- Sponsor
- Carelon Research